Salivary Gland Cancer - Pipeline Review, H2 2014


#238874

52pages

Global Markets Direct

$ 2000

In Stock

Salivary Gland Cancer - Pipeline Review, H2 2014

Summary

Global Markets Directs, Salivary Gland Cancer - Pipeline Review, H2 2014, provides an overview of the Salivary Gland Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Salivary Gland Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Salivary Gland Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Salivary Gland Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Salivary Gland Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Salivary Gland Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Salivary Gland Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Salivary Gland Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Salivary Gland Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Salivary Gland Cancer - Overview 7
Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8
Salivary Gland Cancer - Therapeutics under Development by Companies 9
Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10
Salivary Gland Cancer - Pipeline Products Glance 11
Clinical Stage Products 11
Salivary Gland Cancer - Products under Development by Companies 12
Salivary Gland Cancer - Products under Investigation by Universities/Institutes 13
Salivary Gland Cancer - Companies Involved in Therapeutics Development 14
AstraZeneca PLC 14
Bayer AG 15
Incuron, LLC 16
Novartis AG 17
Otsuka Holdings Co., Ltd. 18
Salivary Gland Cancer - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
AZD-5312 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Dendritic Cell Therapy for Oncology - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
dovitinib lactate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
mepacrine - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
OPB-111001 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
regorafenib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Salivary Gland Cancer - Recent Pipeline Updates 41
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products under Development for Salivary Gland Cancer, H2 2014 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Products under Investigation by Universities/Institutes, H2 2014 13
Salivary Gland Cancer - Pipeline by AstraZeneca PLC, H2 2014 14
Salivary Gland Cancer - Pipeline by Bayer AG, H2 2014 15
Salivary Gland Cancer - Pipeline by Incuron, LLC, H2 2014 16
Salivary Gland Cancer - Pipeline by Novartis AG, H2 2014 17
Salivary Gland Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 25
Number of Products by Stage and Molecule Type, H2 2014 27
Salivary Gland Cancer Therapeutics - Recent Pipeline Updates, H2 2014 41

List of Figures
Number of Products under Development for Salivary Gland Cancer, H2 2014 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 11
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Top 10 Targets, H2 2014 20
Number of Products by Stage and Top 10 Targets, H2 2014 20
Number of Products by Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 22
Number of Products by Top 10 Routes of Administration, H2 2014 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 24
Number of Products by Top 10 Molecule Types, H2 2014 26
Number of Products by Stage and Top 10 Molecule Types, H2 2014 26